Nucleic Acid Drug and RNA Vaccine Industry Summit, September, Shanghai Conference Theme 1:Special topic 2 on innovative research and development of nucleic acid drugs and breakthroughs in new technologies:Process development and quality control
The following article comes from Yaodu D. The author Yaodu D released Yaodu D, focusing on the latest progress in domestic pharmaceutical research and development, and your one-stop drug research and development information assistant! Yao Du Xiao D, see you every day!
** Job name:**BD Sales ** ****** Reported object:** Sales Director/Group CEO *** Salary:** Basic salary + performance bonus + commission bonus ** Group headquarters:** Room 105, Haohai Building, Shangdi Fifth Street, Haidian District, Beijing City *** Working location:** Jinan Licheng District Biomedical Park, Shandong Province *** Job responsibilities...
Peptide drugs have the advantages of clear targets and good drug properties, and have become one of the hot spots in new drug research. At present, globally approved polypeptide drugs have been widely used in many treatment fields such as metabolism and endocrine system, immune system, and musculoskeletal system. In particular, the popular weight-loss drugs of semiglutide and tierpositide in the past two years. The market demand is growing steadily and has huge potential for future development. Although polypeptide drugs have low membrane permeability, short half-life, and rapid elimination in vivo, new modification and production technologies have enabled the development of polypeptide drugs to overcome various difficulties. In addition, artificial
The research and development of innovative drugs by relevant units of the organizer, Pharmaceutical and Chemical Industry Committee of the China Chemical Enterprise Management Association, involves multiple fields and links, including pharmacodynamics, pharmacokinetics, safety evaluation, clinical, etc., and each link has its own special requirements and challenges. To improve R & D efficiency and quality and accelerate the marketing process, non-clinical and translational medicine research plays a vital role in biopharmaceutical research and development. At the same time, in recent years, China has targeted innovative drugs for non-clinical...
The Quality Assurance Department (QAU) of each relevant unit of the organizer, Pharmaceutical and Chemical Industry Committee of the China Chemical Enterprise Management Association, is mainly responsible for GLP compliance supervision within GLP institutions. Its purpose is to promptly discover problems existing in various departments or project implementation, discover them as soon as possible, correct them as soon as possible, and avoid the expansion of defects. As a specially established and relatively independent third party within the GLP laboratory, QAU's work focuses on objectivity and authenticity...
On January, the 19th live broadcast of the innovative drug research and development series video program "Drug Precision" planned and produced by Fan Shengzi came to a successful conclusion. This conference invited many experts and scholars from innovative pharmaceutical companies, clinical institutions, scientific and technological services, etc. to discuss the clinical development of tumor ADC drugs, small molecule drugs, and dual antibody drugs, as well as the application of accompanying diagnosis in the development of tumor-targeted drugs. They shared the latest research results and clinical application experience in their respective fields, attracted hundreds of pharmaceutical elites to participate, and presented a meeting for participants.
On September, Wuhan Ruijian Pharmaceutical Technology Co., Ltd.(Ruijian Pharmaceutical)'s breakthrough ophthalmic product NS was awarded Orphan Drug Certification (ODD, ODD) by the U.S. FDA. This product is aimed at "retinitis pigmentosa
Event time (Friday):: Activities In recent years, the global nuclear drug market has developed vigorously. As more and more therapeutic drugs are launched, the global nuclear drug market has reached about 100 million US dollars annually. From the perspective of the domestic market, China has huge room for development of radiopharmaceuticals. However, due to the certain half-life and radioactivity of nuclide drugs, the research and development of nuclear drugs,
The following article is from Kaijie Life Sciences. The author Kaijie Life Sciences QIAGEN is the world's leading supplier of sample preparation and analysis technology. Relying on its world-leading technology and expertise, the company continues to expand the market from sample preparation, analysis to data interpretation. In academic research, applied testing, biomedicine and molecules
